TNFRSF17 and lymphoma: To assess whether BCMA can be used as a target in B-NHL and CLL, we studied whether BCMAxCD3 BsAb (teclistamab, JNJ-7957) could mediate T-cell activation as well as killing of the lymphoma cell lines.